Wegovy vs Mounjaro: Which Suits Your Needs?
Wegovy Dose Compared to Mounjaro: Key Mechanism Differences
When considering Wegovy dose compared to Mounjaro, the fundamental distinction lies in their active ingredients and receptor targeting. Wegovy contains semaglutide, a selective GLP-1 receptor agonist that mimics your body's natural incretin hormone to reduce appetite and promote satiety after meals. This single-pathway approach has been extensively studied in the landmark STEP clinical trial programme, demonstrating consistent efficacy across diverse patient populations.
Mounjaro operates through a dual mechanism, with tirzepatide targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual agonist approach theoretically provides broader metabolic effects, though both treatments require prescription-only medicine status and must be used alongside lifestyle modifications. The choice between these mechanisms often depends on individual patient factors, previous treatment responses, and clinical assessment outcomes during your consultation with our prescribing team.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
Understanding the financial commitment for each Wegovy dose compared to Mounjaro helps inform your treatment decision. Wegovy starts at £79.99 for the initial 0.25mg dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the maintenance 2.4mg dose. New customers can apply code FIRST40 at checkout, while returning patients use DOSE25 to reach these final prices. Our bundle options provide convenience for multi-month supply, such as the Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99.
Mounjaro pricing follows a different structure reflecting its distinct dosing schedule, with costs varying across the 2.5mg to 15mg range. Both treatments represent significant investment in your health journey, but the per-dose comparison reveals competitive positioning. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine medicines with proper cold-chain storage and next-day delivery throughout the UK, regardless of which treatment your prescriber recommends following clinical assessment.
Clinical Evidence for Wegovy Dose Escalation vs Mounjaro
The STEP clinical trial programme provides robust evidence for Wegovy's dose escalation protocol, with STEP 1 demonstrating approximately 15% average weight reduction at 68 weeks when patients followed the prescribed dosing schedule alongside diet and exercise modifications. The systematic progression from 0.25mg to 2.4mg over 16 weeks allows for optimal tolerance whilst achieving therapeutic benefit, as documented by Wilding et al., NEJM, 2021.
Mounjaro's clinical evidence stems from the SURMOUNT trial series, showing efficacy across its six-dose range with different patient populations. When comparing Wegovy dose escalation to Mounjaro's approach, both treatments demonstrated significant efficacy in their respective trials, though direct head-to-head comparisons remain limited due to different study designs and patient characteristics.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy's semaglutide targets GLP-1 receptors in your brain's appetite control centres, mimicking the natural hormone that signals fullness after eating. This mechanism reduces food cravings and helps you feel satisfied with smaller portion sizes, supporting adherence to reduced-calorie dietary plans. The weekly injection maintains consistent hormone levels, avoiding the peaks and troughs associated with daily medications. As dose escalation progresses from 0.25mg to 2.4mg, the therapeutic effect strengthens whilst allowing your body to adapt gradually. Each dose increment serves a specific purpose in achieving optimal appetite regulation without compromising tolerability or treatment compliance.
Ordering Process: From Assessment to Delivery
Starting your Wegovy dose compared to Mounjaro evaluation begins with our comprehensive 3-minute online clinical assessment, covering medical history, current medications, weight management goals, and lifestyle factors. Our qualified prescribers review applications within 3 working days (24 hours with express service), ensuring appropriate treatment selection based on MHRA licensing criteria and NICE guidelines. Once approved, your chosen treatment ships via next-day delivery using temperature-controlled packaging to maintain medicine integrity. We provide detailed injection technique guidance, dose escalation schedules, and ongoing support throughout your treatment journey. Our pharmacy team remains available for questions about storage, administration, or treatment progression as you advance through the prescribed dosing protocol.
Storage and Practical Considerations
Storage requirements represent a crucial practical difference when weighing Wegovy dose compared to Mounjaro options. Wegovy pens require refrigeration at 2-8°C before first use but can remain at room temperature (below 30°C) for up to 6 weeks once removed from the fridge. This flexibility proves invaluable for travel, work schedules, or situations where refrigeration access is limited. Mounjaro offers only 21 days at room temperature, potentially constraining lifestyle flexibility. Both treatments use pre-filled FlexTouch pens designed for simple self-administration, with dose escalation schedules clearly marked on packaging. Proper storage maintains medicine potency and ensures optimal therapeutic outcomes throughout your treatment course.
Dose Frequency and Lifestyle Integration Comparison
Both Wegovy and Mounjaro follow once-weekly injection schedules, but their dose escalation patterns differ significantly in duration and complexity. Wegovy's five-dose progression spans 16 weeks before reaching maintenance therapy, providing a structured pathway that most patients tolerate well. The predictable schedule helps establish routine and allows healthcare providers to monitor progress systematically. Mounjaro's six-dose escalation offers additional flexibility for dose optimisation, potentially extending the titration period based on individual response and tolerability.
Integration with daily life proves similar for both treatments, though the different maintenance doses may influence long-term convenience and cost considerations. Weekly injection timing can align with your schedule, whether that's Sunday meal preparation or Friday evening routine. Both prescription-only medicines require consistent adherence to achieve the clinical outcomes demonstrated in their respective trial programmes.
Complete Treatment Decision Support
Making an informed choice between Wegovy dose compared to Mounjaro requires considering multiple factors beyond just efficacy data. Your medical history, previous weight management experiences, lifestyle requirements, and treatment goals all influence the optimal selection. Our clinical team evaluates these comprehensive factors during the prescription assessment, ensuring alignment with MHRA licensing criteria and NICE recommendations. Both treatments offer proven efficacy when used appropriately, with the choice often depending on individual patient characteristics rather than superiority of one approach over another. EverydayMeds stocks both treatments, providing flexibility for prescribers to recommend the most suitable option without supply constraints affecting clinical decision-making. Whether you begin with Wegovy's 0.25mg starter dose or Mounjaro's initial strength, our pharmacy supports your complete treatment journey with expert guidance, reliable supply, and ongoing clinical oversight to optimise your weight management outcomes.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
